All In Biotech

NDA 022318 · Genzyme

Renvela

Sevelamer Carbonate · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Apr 30, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Aug 12, 2009

Approved uses

2

Original approval plus efficacy supplements

Registered trials

60

23 Phase 3, 1 recruiting

FAERS reports

11,505

5,643 serious, 1,228 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 25, 2025.

Sevelamer carbonate is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis. Sevelamer carbonate is a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis. ( 1 )

Mechanism: Sevelamer carbonate is a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the gastrointestinal tract and decreasing absorption, sevelamer carbonate lowers the phosphate concentration in the serum (serum phosphorus).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 25, 2016 Supplement 8 · Efficacy · priority review LetterLabel
  • Aug 12, 2009 Original approval · Type 3 - New Dosage Form LabelLetterReview
2 products under this application
  • RENVELA · SEVELAMER CARBONATE 2.4GM/PACKET · FOR SUSPENSION, ORAL · Discontinued · TE AB
  • RENVELA · SEVELAMER CARBONATE 800MG/PACKET · FOR SUSPENSION, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sevelamer Carbonate" as an intervention, any sponsor and status, largest first.

All 60 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • constipation2,548
  • diarrhoea1,057
  • pruritus1,009
  • nausea819
  • chronic kidney disease676
  • end stage renal disease674
  • renal failure666
  • death628
  • vomiting533
  • acute kidney injury515
  • abdominal pain308
  • nephrogenic anaemia298

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20084
200954
201074
2011165
2012239
20131,071
20143,605
2015890
2016678
2017875
2018824
2019790
2020487
2021368
2022277
2023262
2024273
2025355
2026214

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Renvela (Sevelamer Carbonate)

2024 spending

$38.0M

Beneficiaries

8,189

27,433 claims

Per beneficiary

$4,639

$6.39 per unit

View as table
YearSpending
2020$296,303,290
2021$193,692,542
2022$144,276,421
2023$114,323,301
2024$37,991,213

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 45 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.